Racial differences in long-term prostate cancer specific mortality following conservative management for low-risk prostate cancer: A population-based study.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 121-121
Author(s):  
Grace L. Lu-Yao ◽  
Nikita Nikita ◽  
Scott W Keith ◽  
Joshua Banks ◽  
Nathan Handley ◽  
...  

121 Background: It is uncertain whether the same criteria for active surveillance can be applied universally across races. This population-based study was undertaken to quantify racial differences in long-term risk of prostate cancer-specific mortality (PCSM) among patients with low-risk prostate cancer (PCa) receiving conservative management. Methods: We used the Surveillance, Epidemiology, and End Results (SEER) database to identify patients who had low-risk PCa (T1-T2a & Gleason 6 & PSA ≤ 10 ng/mL & N0 & M0) diagnosed in 2004 – 2015 and did not receive radical prostatectomy or radiation therapy within one year of diagnosis. Kaplan-Meier analysis was used to calculate PCSM. The Clopper-Pearson method was used to calculate associated 95% confidence intervals. Hazard ratio of PCSM among those with a high PSA (PSA 4-10) compared to those with a low PSA (PSA < 4) was calculated using Cox proportional hazards models adjusted for covariates (including age, race, marital status, insurance status, U.S. region, year of diagnosis, and AJCC clinical tumor stage). Results: Among 33,740 patients with low-risk PCa, long-term PCSM varied with race and PSA levels at diagnosis. For instance, 10-year PCSM was 2.62% (95% CI: 1.15%-5.05%) among African Americans with PSA 4-10 and 0.98% (95% CI:0.16%-3.12%) among Caucasian patients with PSA < 4. There was no significant statistical interaction between race and PSA level on PCSM (p = 0.81). After adjusting for potential confounders, men with PSA 4-10 experienced 2-fold higher PCSM relative to those with PSA < 4 (HR = 1.96, p = 0.011) and African Americans men experienced a 43% higher PCSM compared to Caucasians (HR = 1.43, p = 0.03). Conclusions: Among men diagnosed with low-risk PCa, long-term PCSM varies by race and PSA at diagnosis. More refined risk stratification may improve PCa management among low-risk PCa patients. [Table: see text]

2014 ◽  
Vol 191 (4S) ◽  
Author(s):  
Erin Ohmann ◽  
Stacy Loeb ◽  
David Robinson ◽  
Anna Bill-Axelson ◽  
Anders Berglund ◽  
...  

2014 ◽  
Vol 12 (5) ◽  
pp. e189-e195 ◽  
Author(s):  
Brandon A. Mahal ◽  
Ayal A. Aizer ◽  
David R. Ziehr ◽  
Andrew S. Hyatt ◽  
Toni K. Choueiri ◽  
...  

2018 ◽  
Vol 122 (6) ◽  
pp. 1003-1009 ◽  
Author(s):  
Evan Kovac ◽  
Emily A. Vertosick ◽  
Daniel D. Sjoberg ◽  
Andrew J. Vickers ◽  
Andrew J. Stephenson

2019 ◽  
Vol 26 (4) ◽  
Author(s):  
S. Roy ◽  
M. E. Hyndman ◽  
B. Danielson ◽  
A. Fairey ◽  
R. Lee-Ying ◽  
...  

Background  Active surveillance instead of active treatment (at) is preferred for patients with low-risk prostate cancer (LR-PCa), but practice varies widely. We conducted a population-based study to assess the proportion of patients who underwent at between January 2011 and December 2014, and to evaluate factors associated with AT.Methods  The provincial cancer registry was linked to administrative health datasets to identify patients with LR-PCa and to acquire demographic, tumour, and treatment data. The primary outcome was receipt of at during the first 12 months after diagnosis, defined as any receipt of external-beam radiotherapy, brachytherapy, radical prostatectomy, cryotherapy, or androgen deprivation. Univariate and multivariate logistic regression were used to analyze the correlation between patient and tumour factors and AT.Results  Of 1565 patients with LR-PCa, 554 (35.4%) underwent at within 12 months of diagnosis. Radical prostatectomy was the most common treatment (58%), followed by brachytherapy (29.6%). Younger age [odds ratio (or) 0.92; 95% confidence interval (ci): 0.91 to 0.94], lower score (≥3) on the Charlson comorbidity index (OR: 0.36; 95% ci: 0.19 to 0.68), T2 stage (or: 3.05; 95% ci: 2.03 to 4.58), higher prostate-specific antigen (PSA) at diagnosis (or: 1.13; 95% ci: 1.06 to 1.21), radiation oncologist consultation (or: 3.35; 95% ci: 2.55 to 4.39), and earlier diagnosis year (2012 or: 0.46; 95% ci: 0.34 to 0.63; 2013 or: 0.45; 95% ci: 0.32 to 0.63; 2014 or: 0.33; 95% ci: 0.23 to 0.47) were associated with a higher probability of AT.Conclusions  This contemporary population-based study demonstrates that approximately one third of patients with LR-PCa undergo at. Patients of younger age, with less comorbidity, a higher tumour stage, higher PSA, earlier year of diagnosis, and radiation oncologist consultation were more likely to undergo AT. Further investigation is needed to identify strategies that could minimize overtreatment.Key Words Prostate cancer, low-risk; active surveillance; active treatment; radiotherapy; brachytherapy; radical prostatectomy


Sign in / Sign up

Export Citation Format

Share Document